Work

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4509

Authors: Nizar M. Tannir, Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Deborah J.L. Wong, Michael Korn, Raid Aljumaily, Karen A. Autio, Shubham Pant, Todd Michael Bauer, Alexandra Drakaki, Naval Guastad Daver, Annie Hung, Peter Van Vlasselaer, Joseph Leveque, Martin Oft

Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, South Texas Accelerated Research Therapeutics, University of California, Los Angeles, Caris Life Sciences (United States), University of Oklahoma Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891556645

Cites:

Cited by: 10

Related to: 10